Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00823862 | Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection | PHASE1 | COMPLETED | 34 | — | — | Oct 1, 2008 | Feb 1, 2010 | Apr 16, 2019 | 5 | Poland |
| Arm | Type | Description |
|---|---|---|
| Active (SD-101) | EXPERIMENTAL | SD-101 in cohorts of escalating doses |
| Name | Type | Description |
|---|---|---|
| SD-101 | DRUG | Intramuscular (IM) |
| ribavirin | DRUG | oral, 2 times per day, for 2 months |
Inclusion Criteria: * Signed, written, informed consent * Male or female subjects, 18 to 55 years of age. * Subject must have chronic infection HCV, genotype 1. * Serum HCV-RNA concentrations 100,000 IU/mL to 10,000,000 IU/mL * No prior treatment for HCV. * Must be negative for hepatitis B (HBV) an...